Clinical-stage biopharmaceutical company Kyverna Therapeutics Inc. (KYTX) is advancing its neuroimmunology pipeline with multiple late-stage programs, including a registrational Phase 3 trial for KYV-101 in generalized myasthenia gravis or MG.
The trial, part of the broader KYSA-6 study, is expected to enroll about 60 adult patients and begin recruitment by the end of 2025. This pivotal study will evaluate KYV-101, a fully human, autologous CD19-directed CAR T-cell therapy, against standard-of-care treatment to demonstrate meaningful improvements in MG-ADL and QMG scores at 24 weeks.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.